Wang, Lixin
Luo, Jianmin
Chen, Guofeng
Fang, Meiyun
Wei, Xudong
Li, Yinghua
Liu, Zhuogang
Zhang, Yin
Gao, Sujun
Shen, Jianliang
Wang, Xin
Gao, Xiaoning
Zhou, Wei
Ma, Yigai
Liu, Hui
Li, Xinquan
Yang, Linhua
Sun, Kai
Funding for this research was provided by:
National Natural Science Foundation of China (81670162, 81470010)
National Natural Science Foundation of China (81350004)
Article History
Received: 22 April 2020
Accepted: 19 August 2020
First Online: 1 September 2020
Ethics approval and consent to participate
: This single-arm, multicenter, prospective clinical trial evaluated the safety and efficacy of the CDCAG regimen in patients with r/r AML (NCT02886559). This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board at each participating institution. All patients enrolled in the study provided written informed consent.
: Not applicable.
: The authors declare that they have no competing interests.